Literature DB >> 3863424

Cytogenetic diagnosis of cancer from body fluids.

L R Bousfield, M L Greenberg, F Pacey.   

Abstract

Serous effusions from 50 patients suspected of having cancer were subjected to cytogenetic analysis by the use of a simple direct technique. Within 24 hours the specimens were reported as unsatisfactory or as positive or negative for malignancy, according to specific chromosomal criteria, which included hypodiploidy. Reports were sent directly to referring clinicians, who also received independently derived findings from routine cytologic study. The value of cytogenetic analysis was clearly shown in this situation, in which the chromosomal findings took the form of an independent second opinion in clinical assessment. There were no false-positive results in any of the 16 cases diagnosed by cytogenetic analysis. Furthermore, in six of these, the initial cytologic report was equivocal, and the repeat sample from three of these failed to yield material suitable for a definite cytologic diagnosis of malignancy. Negative cytogenetic findings also supported the use of cytogenetic analysis as an adjunct to cytologic examination: 23 of the 24 negative cytogenetic reports proved to be accurate, whereas in 8 of these cases the first cytologic report was equivocal. There was one cytogenetic false negative, in which, after retrospective analysis, chromosomal criteria of malignancy were found.

Entities:  

Mesh:

Year:  1985        PMID: 3863424

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  2 in total

1.  Diagnostic utility of the cell block method versus the conventional smear study in pleural fluid cytology.

Authors:  Udasimath Shivakumarswamy; Surekha U Arakeri; Mahesh H Karigowdar; Br Yelikar
Journal:  J Cytol       Date:  2012-01       Impact factor: 1.000

2.  Interphase fluorescence in situ hybridization improves the detection of malignant cells in effusions from breast cancer patients.

Authors:  N Zojer; M Fiegl; J Angerler; L Müllauer; A Gsur; S Roka; M Pecherstorfer; H Huber; J Drach
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.